No randomised trial of prostate-cancer screening in Norway.
The Norwegian Urological Cancer Group (NUCG) decided against participating in the European Randomised Study on Screening for Prostate Cancer, to which they had planned to contribute data from a population of 75 000 men aged between 50 and 65. The plan was abandonned for three main reasons: Norwegian doubts about the statistical power of the trial, the possible ethical implications of screening a large number of men with no symptoms, and the belief that the trial would not produce clinically important results. In this review, the NUCG's reasons for not participating in the trial are discussed in full.
Fosså
S D
SD
Norwegian Radium Hospital, Oslo. s.d.fossa@klinmed.uio.no
Eri
L M
LM
Skovlund
E
E
Tveter
K
K
Vatten
L
L
D000368:Aged; D005060:Europe; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009664:Norway; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000592:standards
D017430:Prostate-Specific Antigen